Content reflects the views of the posting party and is provided for informational purposes only. It does not constitute a solicitation, recommendation, endorsement, or investment advice by BioTech Funding Portal. All content is subject to the portal’s Community Content Guidelines.
Muscle Matters: The Lean-Mass Problem with Appetite-Based Weight Loss
GLP-1 receptor agonists have revolutionized obesity treatment, making significant weight loss pharmacologically achievable for millions of patients. However, these medications come with notable trade-offs. From a clinical perspective, one of the most concerning is the simultaneous loss of muscle mass. Studies show that when patients lose weight on GLP-1 medications, more than 30% of the lost ...more
Energesis’ Energy Expenditure Approach to Obesity: Brown Fat, GLP-1s, and the Competitive Landscape
Energesis
GLP-1 drugs such as semaglutide and tirzepatide have changed the obesity treatment landscape. They have helped many people lose meaningful weight and have made obesity one of the most important areas in medicine today.
But we do not believe they are the end of the story.
The GLP-1 therapies work by reducing appetite and food intake. This can be effective, but it addresses only one side of the body-w...more
- 1
